The process of oral immunotherapy (OIT) consists of a series of dose escalations with the immediate goal of inducing desensitisation and
ultimately achieving a state of tolerance.
Owing to the limitations of OIT, including side-effects and lack of proven efficacy in long-term tolerance induction, it is not yet
recommended in routine clinical practice and should be restricted to the research setting.
Studies using anti-immunoglobulin E (IgE) antibody in food allergy management are limited, but show promising results. The possible
applications are for increasing the sensitivity threshold to certain foods such as peanut, and also for use in combination with OIT to enhance
safety and rapidity of the OIT process; however, anti-IgE is not yet licensed for use in food allergy.